Hepatocellular Carcinoma Clinical Trial
Official title:
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 6th most common cancer and the third most frequent
cause of cancer death worldwide. Hepatic resection (HR) has been the standard treatment
modality for HCC aiming at clinical cure. In both Europe and Unit States proposed guidelines
for HCC, HR was recommend only for patients with a single HCC lesion and preserved liver
function . Unfortunately, only 10%-30% of HCCs are amenable to such "curative" surgical
resection at the time of diagnosis, because of tumor multifocality, portal vein invasion, and
underlying advanced liver cirrhosis . Alternatively, transarterial chemoembolization (TACE)
has become the most popular modality for palliative treatment for the other patients.
However, the long term outcomes were generally poor for HCC patients treated with TACE.
Recently, sorafenib has shown some promises in improvement of 3-month survival among patients
with advanced HCC. It is claimed that sorafenib has become the standard of care for patients
advanced HCC.
Thus, the purpose of this study was to prospectively compare the effectiveness of sorafenib
combined with TACE with that of TACE alone in the treatment of unresectable HCC .
Hepatocellular carcinoma (HCC) is a common cause of cancer mortality in Asia. Most patients
present with intermediate or advanced disease. Percutaneous ethanol injection, radiofrequency
ablation, and transcatheter arterial chemoembolization (TACE) are not considered as a
curative treatment and have achieved very limited success in eradicating large HCC.
Two phase III trials were shown to be efficacious and well-tolerated in patients with
advanced HCC. Median overall survival was significantly 2 to 3 months longer in the sorafenib
group than that in the placebo. It is interesting to recognize the combined therapeutic
effect of TACE with sorafenib. The proposed study will make an important contribution to
understanding not only the safety and efficacy of sorafenib in addition to TACE in patients
diagnosed with unresectable HCC, but this will also be the first clinical trial prospectively
to compare the effectiveness of sorafenib combined with TACE with that of TACE alone in the
treatment of unresectable HCC
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
| Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
| Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
| Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
| Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
| Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
| Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
| Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
| Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
| Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |